Get the Stockscreener App
25.21
2.74%
-0.71
After Hours:
25.25
0.04
+0.16%
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $25.21, with a volume of 119.39M.
It is down -2.74% in the last 24 hours and down -0.47% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$25.92
Open:
$25.581
24h Volume:
119.39M
Relative Volume:
3.18
Market Cap:
$143.68B
Revenue:
$63.32B
Net Income/Loss:
$7.52B
P/E Ratio:
19.33
EPS:
1.3043
Net Cash Flow:
$9.48B
1W Performance:
-3.67%
1M Performance:
-0.47%
6M Performance:
+0.68%
1Y Performance:
+5.57%
1-Day Range:
$24.94
$25.66
1-Week Range:
$24.94
$26.49
52-Week Range:
$23.11
$28.75
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.21 | 143.68B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,098.57 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
228.39 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
216.49 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
113.87 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
147.08 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Upgrade | Argus | Hold → Buy |
| Feb-25-26 | Initiated | RBC Capital Mkts | Underperform |
| Feb-20-26 | Initiated | Barclays | Underweight |
| Feb-12-26 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-02-25 | Resumed | Citigroup | Neutral |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer StockWeekly sector check after pneumococcal vaccine update - AD HOC NEWS
mRNA Patent Wars Update: Delaware Court Allows Moderna and Pfizer/BioNTech to Assert Laches in GSK Patent Infringement Cases - JD Supra
Appeals Court Scraps Redo Of Pfizer, Flynn Drug Fines - Law360
PFE Stock Slides Following CFO Exit, 2026 Guidance Reaffirmed - TradingView
Pfizer shares dip after CFO departure raises new questions about 2026 outlook - TechStock²
Pfizer CEO on leaving Europe in pursuit of the American dream: The ‘opportunities are enormous’ - New York Post
Key facts: Pfizer Reaffirms FY26; CFO Denton Exits Aug 15; Guegan Int. - TradingView
Pfizer reaffirms outlook after CFO exit (update) - MSN
Pfizer reaffirms 2026 financial guidance following CFO transition By Investing.com - Investing.com India
Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook - Yahoo Finance
Stock Market Today, June 18: Pfizer Falls as CFO Transition Tests Confidence in 2026 Outlook - The Motley Fool
Pfizer (PFE) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Pfizer Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Pfizer CFO departs for consumer goods sector - CFO Dive
Pfizer Shares Dip 1.5% as CFO Dave Denton Announces Exit - TradingView
Pfizer CFO Exit Adds Pressure - TradingView
Pfizer reaffirms 2026 financial guidance following CFO transition - Investing.com
Pfizer reaffirms outlook after CFO exit (update) (PFE:NYSE) - Seeking Alpha
Pfizer reafffirms 2026 guidance after CFO transition announcement By Investing.com - Investing.com Canada
Pfizer reafffirms 2026 guidance after CFO transition announcement - Investing.com
Pfizer Stock Drops Today As CFO Steps Down In August - Benzinga
Pfizer (PFE) Names Cecile Guegan Interim CFO As Dave Denton Prepares To Exit - Yahoo Finance
Why Accenture, Pfizer, and Kroger are moving today - Yahoo Finance
Pfizer Slides as Investors Appear to Reassess Near-Term Growth Catalysts - Quiver Quantitative
Pfizer (PFE) Shares Sink 3% Following CFO Dave Denton’s Resignation Announcement - Blockonomi
Pfizer (PFE) Shares Slide 3% Following CFO Dave Denton’s Departure Announcement - Blockonomi
Pfizer (PFE) Shares Sink After Surprise CFO Exit - TipRanks
Pfizer CFO Dave Denton to step down, interim CFO appointed - grafa.com
Pfizer Names Cecile Guegan Interim CFO Following Dave Denton’s Departure - citybiz
Pfizer CFO Dave Denton to leave company in August - Reuters
Can Pfizer Take Share From Lilly & Novo Nordisk in the Obesity Space? - Yahoo Finance
Pfizer launches CFO search as Denton plans to depart in August - Crain's New York Business
Pfizer Announces Search for New Chief Financial Officer - Contract Pharma
Living Longer with Cancer: Redefining What It Means to Survive - Pfizer
Pfizer supporting employees with migraine through flexible work arrangements, raising awareness about condition - Benefits Canada.com
Pfizer Shares Slip Following CFO Transition Announcement - Yahoo Finance
Pfizer CFO Dave Denton to step down, leave company in August - BNN Bloomberg
Pfizer CFO Dave Denton stepping down in August 2026 - Yahoo Finance
Pfizer CFO Dave Denton to return to consumer goods roots - FirstWord Pharma
Pfizer Launches CFO Search as Denton Plans to Depart in August - Bloomberg.com
Pfizer CFO Dave Denton to step down, Cecile Guegan named interim - Investing.com
Pfizer stock falls as CFO Dave Denton to step down in August - Investing.com
Pfizer CFO Dave Denton to Step Down; Cecile Guegan Named Interim CFO - TradingView
Pfizer Chief Financial Officer Dave Denton to Leave - marketscreener.com
Pfizer Announces Chief Financial Officer Transition - Business Wire
Pfizer CFO Dave Denton to Depart; Interim CFO Named - marketscreener.com
Pfizer CFO Dave Denton to step down in August - Breakingthenews.net
Pfizer Inc. (PFE) Discusses New Phase IIb Data and Development Plans for Berobenatide GLP-1 Receptor Agonist in ObesitySlideshow (NYSE:PFE) 2026-06-17 - Seeking Alpha
Pfizer: Why I'm Still Expecting A Massive Rebound (NYSE:PFE) - Seeking Alpha
Pfizer Stock And Two AI Healthcare Plays That Look Mispriced - simplywall.st
Questions over Pfizer’s marketing claims resurface as scrutiny grows around blockbuster drug promotion - EU Reporter
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):